ID   Hep-G2/2.2.1
AC   CVCL_3701
SY   HEP-G2/2.2.1; HEP G2/2.2.1; HepG2/2.2.1; Hep 2.2.1
DR   BTO; BTO:0004572
DR   CLO; CLO_0003705
DR   ATCC; CRL-11997
DR   BCRC; 60364
DR   Wikidata; Q54882786
RX   Patent=US5821057;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11997.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Derived from sampling site: Liver.
ST   Source(s): ATCC
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,13
ST   D16S539: 12,13
ST   D5S818: 11,12
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 21
RX   Patent=US5821057;
RA   Chiang J.Y.L., Stroup D.;
RT   "Assay for agents that affect cholesterol 7alpha-hydroxylase
RT   expression and a characterization of its regulatory elements.";
RL   Patent number US5821057, 13-Oct-1998.